Biogen Q2 Results Top Estimates; Boosts FY24 Outlook
(RTTNews) - Biotechnology company Biogen Inc. (BIIB) reported Thursday net income attributable to the company for the second quarter of $583.6 million or $4.00 per share, higher than $591.6 million or $4.07 per share in the prior-year quarter.
Excluding items, adjusted earnings for the quarter were $5.28 per share, compared to $4.02 per share in the year-ago quarter.
On average, 27 analysts polled by Thomson Reuters expected the company to report earnings of $4.02 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the quarter remained relatively flat with the same quarter last year at $2.46 billion. Revenues were up 0.9 percent in constant currency. Analysts expected revenues of $2.38 billion for the quarter.
Looking ahead to fiscal 2024, the company now projects adjusted earnings in a range of $15.75 to $16.25 per share on a revenue decline in the low-single digits. Previously, the company expected adjusted earnings in the range of $15.00 to $16.00 per share on a revenue decline in the mid-single digits.
The Street is looking for earnings of $15.58 per share on a revenue decline of 3.2 percent to $9.53 billion for the year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Biogen Says European Commission Grants TOFIDENCE Biosimilar Approval For Multiple Indications
Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln
Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook
Biogen Says European Commission Revokes Marketing Authorizations For Generic Versions Of TECFIDERA
Biogen Q2 Results Top Estimates; Backs FY23 Outlook
Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook
Biogen Q4 Results Top Estimates
